Oral Biologics Opportunity Target pharma and biopharma buyers seeking patient-friendly biologic delivery; emphasize BioPYM platform to replace injections with oral capsules for GI and systemic biologics, expanding addressable patient base and reducing cold chain requirements.

Strategic Regional Footprint Leverage Halethorpe/Arbutus Maryland location within the BioHealth Capital Region to engage regional hospitals, clinics, and biotech parks for pilot programs, partnerships, and quick regulatory feedback to accelerate clinical adoption.

Clinical and Payer Fit Position BioPYM as cost-saving and patient-centric, highlighting potential reductions in administration costs, needle-associated barriers, and hospital visits, appealing to payers and health systems aiming to improve adherence and outcomes.

Awarded Innovation Cred Leverage the 2022 Mid-Atlantic Innovation Celebration award to build credibility in discussions with strategic investors, CROs, and potential collaborators seeking validated biotech innovations and competitive differentiation.

Growth and Partnerships Identify opportunities with contract manufacturers, CMOs, and supply chain partners to scale production of oral BioPYM candidates; align with funding signals and potential co-development ventures as the company moves toward larger revenue bands.